FOR WOMEN WITH ADVANCED BREAST CANCER, TIME IS PRECIOUS
KISQALI is indicated for the treatment of women with hormone receptor (HR)−positive, human epidermal growth factor receptor 2 (HER2)−negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.* In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.1
*KISQALI is not recommended to be used in combination with tamoxifen.1
With KISQALI + ET*, you can give your HR+/HER2− aBC patients more
time worth having1–10
More time with their loved ones
- KISQALI + ET* is the only CDK4/6i to show statistically significant improvements in OS in three phase III trials3,4,10
The quality time they need
Improved or preserved quality of life vs fulvestrant/NSAI alone5,6
Time with manageable side effects
Manageable and consistent safety profile1–4,7–15
*KISQALI is not recommended to be used in combination with tamoxifen.1
PLEASE SELECT A PATIENT POPULATION AND SETTING TO FIND OUT HOW KISQALI CAN HELP WOMEN WITH HR+/HER2− aBC
Premenopausal women
KISQALI + non-steroidal aromatase inhibitor (NSAI) in first-line premenopausal patient population.
Postmenopausal women
KISQALI + aromatase inhibitor (AI) in first-line postmenopausal patient population.
aBC, advanced breast cancer; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitor; ET, endocrine therapy; HR+/HER2-, hormone receptor-positive/human epidermal growth factor receptor 2-negative; LHRH, luteinising hormone-releasing hormone; NSAI, non-steroidal aromatase inhibitor; OS, overall survival.
- KISQALI (ribociclib). Summary of Product Characteristics.
- Slamon DJ, et al. J Clin Oncol. 2018;36(24):2465–2472.
- Slamon DJ, et al. N Engl J Med. 2020;382(6):514–524.
- Im S-A, et al. N Engl J Med. 2019;381(4):307–316.
- Harbeck N, et al. Ther Adv Med Oncol. 2020;12:1758835920943065.
- Fasching P, et al. Breast. 2020;54:148–154.
- Lu Y-S, et al. Clin Cancer Res. 2022;2(5):851–859.
- De Laurentiis M, et al. J Clin Oncol. 2020;38(15):1055–1055.
- De Laurentiis M, et al. J Clin Oncol. 2018;36(15):1056–1056.
- Hortobagyi GN, et al. N Engl J Med. 2022;386(10):942–950.
- Hortobagyi GN, et al. Ann Oncol. 2018;29(7):1541–1547.
- Tripathy D, et al. Lancet Oncol. 2018;19(7):904–915
- Bardia A, et al. Poster 330P. Presentation at European Society for Medical Oncology Congress, 19-23 October 2018, Munich, Germany.
- Hortobagyi GN, et al. N Engl J Med. 2016;375(18):1738–1748
- Slamon DJ, et al. Presented at ASCO Annual Meeting, 4–8 June 2021.